News | June 21, 2026
LabGenius and LG Chem strike AI-powered deal to develop next-gen tumour-targeting antibody therapy
The collaboration is focused on overcoming a major limitation in existing cancer drugs
The collaboration is focused on overcoming a major limitation in existing cancer drugs
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Exclusive licensing agreement combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering expertise
Indian Pharmacopoeia Commission hosts scientific conclave to brainstorm on strengthening pharmaceutical quality and compliance
The collaboration aims to develop differentiated biologics that offer greater convenience and accessibility for patients
The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027
The landmark legislation has laid the foundation for a skilled, regulated and globally competitive Allied and Healthcare Professional workforce, reshaping healthcare education and delivery across India
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
